Fundz

Fundz Deep Dive

Everything you need to win SK Bioscience — in one platform.

Who to reach, what to say, and why now on SK Bioscience — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on SK Bioscience — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

SK bioscience and Sanofi extend partnership to develop next-generation vaccines

Dec 23, 2024•over 1 year ago

Contract Type

partnership

Description

SK bioscience and Sanofi have extended their partnership to co-develop next-generation pneumococcal conjugate vaccines (PCVs) for both pediatric and adult populations. Sanofi will provide an upfront payment of 75.5 billion won ($52 million) to SK bioscience, with additional milestone payments to follow throughout the drug development process. The deal is an expansion of the two companies’ existing collaboration to develop and commercialize a 21-valent PCV candidate GBP410. The global pneumococcal vaccine market is projected to grow to 14.2 trillion won in 2028, up from 11.9 trillion won.

Company Information

Company

SK Bioscience

About

SK Bioscience is a biotechnology company focusing on developing vaccines and biologics. It aims to enhance global health by developing innovative vaccines and biopharmaceuticals. The company is engaged in research, development, and manufacturing of various vaccine products. Recently, it has improved its performance significantly following the acquisition of IDT BioLogica.

Predictive Intelligence
Strategic

ML-powered predictions for SK Bioscience's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.